Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
Carbon M, Hsieh CH, Kane JM, Correll CU.
J Clin Psychiatry. 2017 Mar;78(3):e264-e278. doi: 10.4088/JCP.16r10832.
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH.
Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.
Assessing Patients for Tardive Dyskinesia.
Kane JM.
J Clin Psychiatry. 2017 Nov/Dec;78(9):e1428. doi: 10.4088/JCP.tv17016tx2c.
Tardive dyskinesia.
Jeste DV, Caligiuri MP.
Schizophr Bull. 1993;19(2):303-15. doi: 10.1093/schbul/19.2.303.
Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia.
Jackson R, Brams MN, Carlozzi NE, Citrome L, Fritz NE, Hoberg AR, Isaacson SH, Kane JM, Kumar R.
J Clin Psychiatry. 2022 Nov 28;84(1):22cs14563. doi: 10.4088/JCP.22cs14563.
The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric Properties.
Chouinard G, Cosci F, Chouinard VA, Alphs L.
Psychother Psychosom. 2023;92(6):359-366. doi: 10.1159/000535113. Epub 2023 Dec 7.
A rating scale for tardive dyskinesia.
Simpson GM, Lee JH, Zoubok B, Gardos G.
Psychopharmacology (Berl). 1979 Aug 8;64(2):171-9. doi: 10.1007/BF00496058.
Deutetrabenazine in the treatment of tardive dyskinesia.
Niemann N, Jimenez-Shahed J.
Neurodegener Dis Manag. 2019 Apr;9(2):59-71. doi: 10.2217/nmt-2018-0042. Epub 2019 Jan 31.
Diazepam in tardive dyskinesia.
Weber SS, Dufresne RL, Becker RE, Mastrati P.
Drug Intell Clin Pharm. 1983 Jul-Aug;17(7-8):523-7. doi: 10.1177/106002808301700705.
Effect of Varenicline on Tardive Dyskinesia: A Pilot Study.
Caroff SN, Gutman AR, Northrop J, Leong SH, Berkowitz RM, Campbell EC.
Clin Psychopharmacol Neurosci. 2021 May 31;19(2):355-360. doi: 10.9758/cpn.2021.19.2.355.
